A recent study indicates that people who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who stop traditional lifestyle regimens.
Findings released in a major medical journal points out that while obese individuals often shed a large proportion of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users buying such drugs need to be cognizant of the danger of rapid rebound weight gain when the medication concludes," warns expert Dr. Susan Jebb.
That rate of regain suggests a reversion to original mass within about a year and a half.
Comparing Therapies
The study, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.
Scientists note that individuals who lose weight through lifestyle changes alone typically see a slower weight regain—perhaps 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Nutrition scientists suggest the mode of action of the drugs is key to understanding the amplified weight return.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to hunger is no longer kept in check, making overeating a significant risk."
A Chronic Issue?
Health authorities advise the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals contend that, due to the significant potential of weight regain, the therapy might need to be ongoing.
This view is reinforced by pharmaceutical companies, who note that the results "underscore the long-term character of excess weight," akin to managing conditions like high blood pressure.
User Experiences
People who have discontinued the jabs explain a powerful resurgence of cravings.
"It felt as if a switch activating and I was suddenly ravenous," said an individual.
The struggle is exacerbated if users have not established sustainable dietary or behavioural changes during treatment.
Growing Interest
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are potent tools for weight loss, they are not a magic fix and maintained weight loss hinges on combined behavioural changes.
